NCT05967351
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Enrolling by Invitation
PHASE3All AgesInterventionalSarepta Therapeutics, Inc.
~400 participants
Updated 2026-02-06 on ClinicalTrials.gov
What's tested:delandistrogene moxeparvovec
At a glance
Recruiting sites
0 of 38 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)
Measured over Up to 10 years
Conditions
Where it's being run
38 sites across 31 statesCalifornia4
Italy3
New York2
Taiwan2
Arkansas1
Colorado1
Florida1
Illinois1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Received delandistrogene moxeparvovec for Duchenne muscular dystrophy in a previous clinical study.
Has (a) parent(s) or legal caregiver(s) or is ≥18 years of age and able to understand and comply with the study visit schedule and all other protocol requirements.
Exclusion
Not applicable
What this trial measures
- Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)Up to 10 years